<?xml version='1.0' encoding='utf-8'?>
<document id="19525682"><sentence text="Drug interaction between clopidogrel and proton pump inhibitors."><entity charOffset="25-36" id="DDI-PubMed.19525682.s1.e0" text="clopidogrel" /></sentence><sentence text="Dual antiplatelet therapy with clopidogrel and aspirin has been shown to reduce recurrent cardiac events in patients with acute coronary syndromes or those who have undergone coronary artery stent placement"><entity charOffset="31-42" id="DDI-PubMed.19525682.s2.e0" text="clopidogrel" /><entity charOffset="47-54" id="DDI-PubMed.19525682.s2.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.19525682.s2.e0" e2="DDI-PubMed.19525682.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19525682.s2.e0" e2="DDI-PubMed.19525682.s2.e1" /></sentence><sentence text=" Clopidogrel, a thienopyridine, is a prodrug that is transformed in vivo to an active metabolite by the cytochrome P450 enzyme system"><entity charOffset="1-12" id="DDI-PubMed.19525682.s3.e0" text="Clopidogrel" /><entity charOffset="16-30" id="DDI-PubMed.19525682.s3.e1" text="thienopyridine" /><pair ddi="false" e1="DDI-PubMed.19525682.s3.e0" e2="DDI-PubMed.19525682.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19525682.s3.e0" e2="DDI-PubMed.19525682.s3.e1" /></sentence><sentence text=" Due to the increased risk of bleeding in patients on dual antiplatelet therapy, concomitant gastrointestinal ulcer prophylaxis with a proton pump inhibitor (PPI) is frequently prescribed" /><sentence text=" Data from recent studies show that PPIs, which are extensively metabolized by the cytochrome system, may decrease the antiplatelet activity of clopidogrel"><entity charOffset="144-155" id="DDI-PubMed.19525682.s5.e0" text="clopidogrel" /></sentence><sentence text=" This article reviews the metabolism of various PPIs and existing data regarding the drug-drug interaction between PPIs and clopidogrel"><entity charOffset="124-135" id="DDI-PubMed.19525682.s6.e0" text="clopidogrel" /></sentence><sentence text="" /></document>